Oncolytics Biotech Inc. Announces Issuance of Key Patent

Oncolytics Biotech Inc. ONCY today announced that it has been granted U.S. Patent, # 7,803,385 entitled "Reoviruses Having Modified Sequences." The patent claims cover methods for making and using modified reoviruses, and pharmaceutical compositions that include modified reoviruses. "This composition of matter patent covers the reovirus variant that Oncolytics is using in its clinical trials with patent protection extending to 2028," said Mary Ann Dillahunty, Vice President of Intellectual Property for Oncolytics. Oncolytics has issued patents that cover methods for treating proliferative disorders using modified adenovirus, HSV, parapoxvirus and vaccinia virus in addition to an extensive patent portfolio covering oncolytic reovirus. Analyze Any Stock FREE! Click Here.